目的 探究紫龍金片聯(lián)合GP方案治療非小細(xì)胞肺癌的臨床療效。方法 選取2015年2月—2017年12月濮陽市油田總醫(yī)院收治的非小細(xì)胞肺癌患者80例為研究對(duì)象，將所有患者隨機(jī)分為對(duì)照組和治療組，每組各40例。對(duì)照組給予GP化療方案：第1、8天靜脈滴注注射用鹽酸吉西他濱，1.0 g/m²；第1天靜脈滴注順鉑注射劑，60 mg/m²，4周為1個(gè)周期，2個(gè)周期為1個(gè)療程。治療組在對(duì)照組的基礎(chǔ)上口服紫龍金片，4片/次，3次/d，連續(xù)治療4周為1個(gè)周期，2個(gè)周期為1個(gè)療程。兩組患者均治療1個(gè)療程。觀察兩組的臨床療效，比較兩組的生活質(zhì)量、血清腫瘤標(biāo)記物和不良反應(yīng)。結(jié)果 治療后，對(duì)照組和治療組的有效率（RR）分別為30.0%、45.0%，疾病控制率（DCR）分別為67.5%、87.5%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，對(duì)照組和治療組的Karnofsky（KPS）評(píng)分提高率分別為37.5%、55.0%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組細(xì)胞角蛋-19片段（Cyfra21-1）、鱗癌相關(guān)抗原（SCC-Ag）水平顯著下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組血清腫瘤標(biāo)記物水平明顯低于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，對(duì)照組和治療組白細(xì)胞減少發(fā)生率分別為70.00%、50.00%；紅細(xì)胞減少發(fā)生率分別為52.50%、32.5%；血小板下降發(fā)生率分別為45.00%、30.00%；惡心嘔吐發(fā)生率分別為82.50%、40.00%；腹瀉發(fā)生率分別為37.50%、27.50%，兩組不良反應(yīng)發(fā)生率比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 紫龍金片聯(lián)合GP方案治療非小細(xì)胞肺癌具有較好的臨床療效，可改善患者生活質(zhì)量，降低Cyfra21-1和SCC-Ag水平，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical study of Zilongjin Tablets combined with GP chemotherapy in treatment of non-small cell lung cancer. Methods Patients (80 cases) with non-small cell lung cancer in Puyang Oilfield General Hospital from February 2015 to December 2017 were randomly divided into control and treatment groups, and each group had 40 cases. Patients in the control group were given GP chemotherapy:intravenously injected Gemcitabine Hydrochloride for injection at the first and eighth day, 1.0 g/m², intravenously injected Cisplatin Injection at the first day, 60 mg/m², 4 weeks were 1 cycle and 2 cycles were 1 course. Patients in the treatment group were po administered with Zilongjin Tablets on the basis of the control group, 4 tablets/time, three times daily, 4 weeks were 1 cycle and 2 cycles were 1 course. Patients in two groups were treated for 1 course. After treatment, the clinical efficacies were evaluated, and the quality of life, serum tumor markers, and adverse reactions in two groups were compared. Results After treatment, the RR in the control and treatment groups were 30.0% and 45.0%, respectively, the DCR in the control and treatment groups were 67.5% and 87.5%, respectively, and there were difference between two groups (P < 0.05). After treatment, the KPS scores in the control and treatment groups were 37.5% and 55.0%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of Cyfra21-1 and SCC-Ag in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And serum tumor marker levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the incidence of leukopenia in the control and treatment groups were 70.00% and 50.00%, respectively; the red blood cells decreased incidence in the control and treatment groups were 52.50% and 32.5%, respectively; the incidence of thrombocytopenia in the control and treatment groups were 45.00% and 30.00%, respectively, the incidence of nausea and vomiting in the control and treatment groups were 82.50% and 40.00%, respectively, the incidence of diarrhea in the control and treatment groups were 37.50% and 27.50%, respectively, and there was difference between two groups (P < 0.05). Conclusion Zilongjin Tablets combined with GP chemotherapy has clinical curative effect in treatment of non-small cell lung cancer, can improve the quality of life, decrease the levels of Cyfra21-1 and SCC-Ag, with good safety, which has a certain clinical application value.